

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

INSIDE INFORMATION AND 2012 POSITIVE PROFIT ALERT

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Listing Rules.

Based on the unaudited consolidated management accounts of the Company prepared in accordance with HKFRS, the net profit of the Group for the year ended 31 December 2012 is expected to be at least 1.5 times of that for the year ended 31 December 2011.

The financial information of the Group for the year ended 31 December 2012 referred to in this announcement has not been audited by the auditor of the Company, and may be different from the audited financial information. The Board confirmed that the disclosure of the financial information of the Group for the year ended 31 December 2012 referred to in this announcement is made after due and careful enquiry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) announces the estimated annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2012 as follows:

(1) Estimated results for the year ended 31 December 2012

Based on the unaudited consolidated management accounts of the Company for the year ended 31 December 2012 prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRS”), the estimated net profit of the Group for the year ended 31 December 2012 is expected to be at least 1.5 times of that for the year ended 31 December 2011. Detailed financial information of the Company will be published in the forthcoming 2012 annual report of the Company.

The financial information of the Group for the year ended 31 December 2012 referred to in this announcement has not been audited by the auditor of the Company, and may be different from the audited financial information. The Board confirmed that the disclosure of the financial information of the Group for the year ended 31 December 2012 referred to in this announcement is made after due and careful enquiry.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

(2) Results of last year

The net profit attributable to the equity holders of the Company for the year ended 31 December 2011 was HK\$104.3 million.

The earnings per share of the Company for the year ended 31 December 2011 was HK\$0.075.

The above financial figures were prepared in accordance with HKFRS.

(3) Reason for estimated results increase

The increase in net profit for the year ended 31 December 2012 is mainly attributable to the following factors:

1. The increase in gain on fair value change of derivative components of convertible bonds;
2. Increase in export sales of the Group's bulk medicine and intermediate products and decrease in overall production costs; and
3. Continued increase in sales of the Group's finished products as a result of the Group's expansion in China's rural market.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Choy Kam Lok
Chairman

Hong Kong, 18 March 2013

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Mr. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.